Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is well-positioned for growth in the medical device industry due to its strong financials, strategic focus on niche products, and potential for expansion through mergers and acquisitions. With consistent double-digit revenue growth and ambitious targets set by management for sales and international revenue, the company is poised to continue its success. However, it must be mindful of potential risks related to compliance and disruptions in its manufacturing and tissue processing services.

Bears say

LeMaitre Vascular is experiencing strong top-line growth driven by grafts, valvulotomes, and carotid shunts, with the EMEA region leading geographically. However, their balance sheet shows a high level of debt and their free cash flow has decreased from the previous year. While the company has filed a claim with the FDA to expand cannulation labeling, this may not have a significant impact on their financials.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.